Burden of cryptococcal meningitis in Malawi.
There is little information about the national burden of cryptococcal meningitis (CM) in African countries affected by the HIV/AIDS epidemic. From April 2005 onwards, we used national supervision visits of all health facilities that provided antiretroviral therapy to collect data on the number of new patients diagnosed and treated for CM in the previous quarters - using mainly fluconazole registers. For two 12-month reporting periods, there were 2125 and 2464 patients suffering from CM, giving an estimated annual incidence of 2.2% and 2.6%, respectively, of those infected with HIV in Malawi. Between 40-50% of all patients with CM were diagnosed and treated at central hospitals; no more than 1% were diagnosed and treated at smaller antiretroviral therapy sites. These data are useful for quantifying the need for better diagnostic reagents and antifungal drugs.
Makombe
Simon D
SD
HIV Unit, Ministry of Health, Lilongwe.
Nkhata
Amon
A
Schouten
Erik J
EJ
Kamoto
Kelita
K
Harries
Anthony D
AD
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D000935:Antifungal Agents / Q000627:therapeutic use*; D003455:Cryptococcus neoformans / Q000187:drug effects*; D015725:Fluconazole / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008295:Malawi / Q000453:epidemiology; D016919:Meningitis, Cryptococcal / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D012042:Registries
D000935:Antifungal Agents; D015725:Fluconazole